Searchable abstracts of presentations at key conferences in endocrinology

ea0012s4 | Society for Endocrinology European Medal Lecture | SFE2006

Assessment of growth hormone levels: Tailor-made assays for specific clinical questions

Strasburger C

Since more than 40 years growth hormone (GH) measurement has been possible by immunoassay techniques. Although these methods have greatly augmented the diagnostic tools of endocrinologists following patients with GH-related disorders, their use has also brought about confusion and left uncertainties.Cut-off levels for dynamic GH tests in the diagnosis of both GH deficiency and acromegaly have to be considered arbitrary, since different commercial hGH ass...

ea0011s63 | Anabolic hormones in sport | ECE2006

Detecting growth hormone abuse in athletes

Strasburger C

Performance enhancing substances enjoy considerable popularity among athletes, particularly if deemed undetectable. Doping with growth hormone has been considered undetectable until recently. Two strategies have been pursued to detect GH doping: Pharmacological endpoints and GH isoform composition.For the former approach the consortium GH 2000/2004 has identified markers of GH action and found a combination of parameters from the IGF-system and collagen ...

ea0035oc7.2 | IGF-1 and Thyroid Basic | ECE2014

The proposed molecular mechanism underlying isolated growth hormone deficiency (IGHD) caused by C53S mutation

Sander Max , Wu Zida , Strasburger Christian J.

Background: Besson A et al. described a patient with homozygous for C53S-hGH suffering from IGHD (JCEM2005 90:2493-9). They observed reduced ability of the mutant to bind and activate GHR in vitro. C53A-hGH lacks the disulfide bond between C53 and C165, which is conserved in GH/prolactin family.Methods: Mouse pituitary AtT-20 cells, HEK-293 and CHO-K1 cells were transfected with plasmids containing C53S, C53A or C53S/C165A cDNA. hGH from cell supernatant...

ea0016p360 | Growth and development | ECE2008

Study of dimer and oligomers of human growth hormone

Junnila Riia , Wu Zida , Strasburger Christian

There is a high heterogeneity of human growth hormone (hGH), variation rising from the different genes in pituitary and placenta, alternative splicing, post-translational modifications, oligomerization and binding to the growth hormone binding protein (GHBP). Distinguishing between different variants remains problematic and there is still quite little information about the proportion of these variants in circulation of both healthy individuals and of patients with growth hormo...

ea0010s19 | Hormone measurements: past, present and future | SFE2005

Detecting growth hormone abuse in athletes

Strasburger C , Bidlingmaier M , Wu Z

Performance enhancing substances enjoy considerable popularity among athletes, particularly if deemed undetectable. Doping with growth hormone has been considered undetectable until recently. Two strategies have been pursued to detect GH doping: Pharmacological endpoints and GH isoform composition.For the former approach the consortium GH 2000/2004 has identified markers of GH action and found a combination of parameters from the IGF-system and collagen ...

ea0020p534 | Growth and Developmental Endocrinology | ECE2009

Characterization of growth hormone (GH) mutants R77C and D112G found in patients with retarded growth

Junnila Riia , Braig Friederike , Piilonen Katri , Strasburger Christian , Wu Zida

Introduction: Two heterozygous missense mutations R77C and D112G have been identified in GH-1 gene of patients with short stature by Takahashi et al. These patients had high serum immunoreactive GH concentrations but low IGF-1 concentrations, indicating bioinactivity of their GH. Separation of GH in patientsÂ’ serum by isoelectric focusing revealed the coexistence of mutant and wild type (wt) GH. In order to understand the molecular mechanism of the isolated GH defi...

ea0020p536 | Growth and Developmental Endocrinology | ECE2009

Development of specific monoclonal antibodies and highly sensitive immunoassays for 20 kDa and 22 kDa human growth hormone (hGH)

Wu Zida , Devany Emral , Lima Giovanna , Bidlingmaier Martin , Strasburger Charistian

The physiological and pathophysiological significance of hGH isoforms remains to be fully elucidated. In order to study the two most abundant hGH isoforms 20 and 22 kDa hGH, we have generated monoclonal antibodies (mAbs) against 20 and 22 kDa hGH. The mAbs against 20 and 22 kDa were characterized for their specificity and epitopes with different binding assays as well as by Western blot. The mAb 1G12 against 20 kDa with lower than 0.05% cross reactivity to 22 kDa hGH combined ...

ea0013p51 | Clinical practice/governance and case reports | SFEBES2007

Medical treatment in adrenal insufficiency: Does the patient’s quality of life differ depending on which glucocorticoid is given?

Bleicken Benjamin , Ventz Manfred , Strasburger Christian J , Quinkler Marcus

Objective: Patients from FRG and West-Berlin with primary (1AI) or secondary (2AI) adrenal insufficiency were treated with hydrocortisone (HC) while in contrast patients from the former GDR received prednisolone (PR). Investigation of our study is to detect any differences in quality of life (QoL) in patients on HC or PR medication.Methods: 350 patients of our outpatient clinic were contacted by mail. Up to now 131 patients took part in the survey. 2 sta...

ea0011p302 | Diabetes, metabolism and cardiovascular | ECE2006

Renal expression of alpha-ENaC is increased in testosterone treated rats

Kienitz T , Allolio B , Strasburger CJ , Quinkler M

Introduction: There is no difference in blood pressure between boys and girls, but following puberty, blood pressure increases more in men than in women. The higher blood pressure and stronger progression of hypertension in men is associated with a higher risk and mortality for cardiovascular diseases than in women. Androgens are known to play an important role in renal tubular epithelial cell growth, hypertrophy and erythropoetin production and may be important determinants o...

ea0007oc15 | Development and growth | BES2004

Internalization of the GH antagonist pegvisomant

Maamra M , Kopchick J , Strasburger C , Ross R

Pegvisomant is a specific GH antagonist developed for the treatment of acromegaly. Pegvisomant is a GH antagonist molecule with an amino acid substitution that blocks the conformational change necessary for signal transduction and polyethylene glycol (PEG) moieties to improve clinical efficacy. Pegvisomant has a long plasma half-life and its mode of clearance has not been established. We hypothesised that GHR mediated internalisation of Pegvisomant might be one mechanism for i...